1. |
Becker K, Uebing A, Hansen JH. Pulmonary vascular disease in Fontan circulation—Is there a rationale for pulmonary vasodilator therapies? Cardiovasc Diagn Ther, 2021, 11(4): 1111-1121.
|
2. |
Al-Shawk M, Banjoko A, Axiaq A, et al. Perioperative and long-term management of Fontan patients. Cardiol Young, 2021, 31(5): 775-785.
|
3. |
Kotani Y, Chetan D, Zhu J, et al. Fontan failure and death in contemporary Fontan circulation: Analysis from the last two decades. Ann Thorac Surg, 2018, 105(4): 1240-1247.
|
4. |
Latus H, Lederle A, Khalil M, et al. Evaluation of pulmonary endothelial function in Fontan patients. J Thorac Cardiovasc Surg, 2019, 158(2): 523-531.
|
5. |
Chugh R. The Fontan thromboprophylaxis dilemma: To give, or what not to give. J Am Coll Cardiol, 2019, 74(8): 1082-1085.
|
6. |
Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: A randomized, double-blind, placebo-controlled, crossover trial. Circulation, 2011, 123(11): 1185-1193.
|
7. |
Rhodes J, Ubeda-Tikkanen A, Clair M, et al. Effect of inhaled iloprost on the exercise function of Fontan patients: A demonstration of concept. Int J Cardiol, 2013, 168(3): 2435-2440.
|
8. |
Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and adults after Fontan operation: The TEMPO (treatment with endothelin receptor antagonist in Fontan patients, a randomized, placebo-controlled, double-blind study measuring peak oxygen consumption) study. Circulation, 2014, 130(23): 2021-2030.
|
9. |
Giardini A, Balducci A, Specchia S, et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in Fontan patients. Eur Heart J, 2008, 29(13): 1681-1687.
|
10. |
伍琼, 贾镭, 荆志成, 等. 曲前列尼尔治疗肺动脉高压的研究进展. 中华心血管病杂志, 2017, 45(9): 810-813.
|
11. |
Ablonczy L, Tordas D, Kis E, et al. Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertension-bridge-to-transplant or long-term treatment? Pediatr Transplant, 2018, 22(2): 1-10.
|
12. |
Constantine A, Dimopoulos K, Jenkins P, et al. Use of pulmonary arterial hypertension therapies in patients with a Fontan circulation: Current practice across the United Kingdom. J Am Heart Assoc, 2022, 11(1): e023035.
|
13. |
Rychik J, Atz AM, Celermajer DS, et al. Evaluation and management of the child and adult with Fontan circulation: A scientific statement from the American Heart Association. Circulation, 2019. [Epub ahead of print].
|
14. |
Vigano G, McMahon CJ, Walsh K, et al. High-risk Fontan completion patients achieve low perioperative risk and benefit from cavopulmonary connection 7 years out. Eur J Cardiothorac Surg, 2019, 56(4): 664-670.
|
15. |
Ozawa H, Hoashi T, Ohuchi H, et al. Long-term outcomes after fenestration closure in high-risk Fontan candidates. Pediatr Cardiol, 2021, 42(6): 1356-1364.
|
16. |
Bigelow AM, Ghanayem NS, Thompson NE, et al. Safety and efficacy of vasopressin after Fontan completion: A randomized pilot study. Ann Thorac Surg, 2019, 108(6): 1865-1874.
|
17. |
农绍汉. 新生儿毛细血管渗漏综合征. 中国当代儿科杂志, 2020, 22(10): 1056-1060.
|